(Q43042183)

12 November 2017

Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

W Jessner

1

1 reference

12 November 2017

R Stauber

2

1 reference

12 November 2017

F Hackl

3

1 reference

12 November 2017

C Datz

4

1 reference

12 November 2017

T Watkins-Riedel

5

1 reference

12 November 2017

H Hofer

6

1 reference

12 November 2017

A Gangl

7

1 reference

12 November 2017

H Kessler

8

1 reference

12 November 2017

P Ferenci

9

1 reference

12 November 2017

language of work or name

1 reference

1 January 2003

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

10

1 reference

12 November 2017

37-42

1 reference

12 November 2017

1

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

12 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Hepatitis C virus resistance to antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00396.X

10.1046/J.1365-2893.2003.00396.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference